Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Input: Consider Input: Context: Carpal tunnel syndrome (CTS) is the most common median nerve neuropathy, accounting for 90% of all neuropathies. Carpal tunnel syndrome presents in 3.8% of the general population, with a higher prevalence among women. There are several risk factors associated with CTS, including both medical and non medical factors. The pathophysiologic mechanisms involved in the median nerve compression and traction are thought to be complex, and as yet are not fully understood. The present review aimed to provide an overview of the pathophysiology of median nerve neuropathy in the carpal tunnel, and subsequent development of CTS. 
 Question: What nerve is involved in carpal tunnel syndrome?

Output: median


Input: Consider Input: Context: As of the census of 2000, there were 35,100 people, 12,759 households, and 9,071 families residing in the county. The population density was 59 people per square mile (23/km). There were 15,035 housing units at an average density of 25 per square mile (10/km). The racial makeup of the county was 85.8% Race (United States Census), 3.9% Race (United States Census) or Race (United States Census), 1.8% Race (United States Census), 1.0% Race (United States Census), 0.1% Race (United States Census), 5.0% from Race (United States Census), and 2.4% from two or more races. 8.9% of the population were Race (United States Census) or Race (United States Census) of any race. 14.9% were of German people, 12.6% English people, 11.7% Irish people, 8.8% Italian people and 7.3% United States ancestry according to Census 2000. 93.1% spoke English language and 5.1% Spanish language as their first language. 
 Question: Were there fewer English speakers or Spanish speakers?

Output: spanish


Input: Consider Input: Context: We describe the use of four complementary biosensors (Biacore 3000, Octet QK, ProteOn XPR36, and KinExA 3000) in characterizing the kinetics of human nerve growth factor (NGF) binding to a humanized NGF-neutralizing monoclonal antibody (tanezumab, formerly known as RN624). Tanezumab is a clinical candidate as a therapy for chronic pain. Our measurements were consistent with the NGF/tanezumab binding affinity being tighter than 10 pM due to the formation of an extremely stable complex that had an estimated half-life exceeding 100 h, which was beyond the resolution of any of our methods. The system was particularly challenging to study because NGF is an obligate homodimer, and we describe various assay orientations and immobilization methods that were used to minimize avidity in our experiments while keeping NGF in as native a state as possible. We also explored the interactions of NGF with its natural receptors, TrkA and P75, and how tanezumab blocks them. The Biacore blocking assay that we designed was used to quantify the potency of tanezumab and is more precise and reproducible than the currently available cell-based functional assays. 
 Question: What is the target of tanezumab?


Output: ngf